This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Journals
    Journal
    13/02/17

    First-line treatment of metastatic melanoma: role of nivolumab

    Historically, the median overall survival of metastatic melanoma patients was less than 1 year and long-term survivors were rare. Recent advances in therapies have dramatically shifted this landscape...

    • Source: ImmunoTargets and Therapy
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    20/04/15

    Phase II study for Opdivo (nivolumab)+Yervoy (ipilimumab) versus Yervoy monotherapy in untreated advanced melanoma- BMS

    BMS has announced positive results from a Phase II trial (CheckMate -069), evaluating the Opdivo (nivolumab)+Yervoy (ipilimumab) regimen versus Yervoy...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    01/06/15

    Opdivo (nivolumab)+ Yervoy (ipilimumab) and Opdivo monotherapy superior to Yervoy in Checkmate 067 trial for advanced melanoma.- BMS

    BMS announced positive results of a Phase III trial (CheckMate -067) evaluating the Opdivo (nivolumab)+Yervoy (ipilimumab) regimen or Opdivo monotherapy...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    26/09/15

    BMS files sBLA at FDA for combination Opdivo (nivolumab) + Yervoy (ipilimumab) to treat advanced melanoma

    BMS announced that the FDA has accepted for filing and review a supplemental Biologics License Application (sBLA) for the combination...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    01/10/15

    FDA grants accelerated approval for Opdivo (nivolumab) + Yervoy (ipilimumab) combination to treat BRAF V600 wild-type metastatic melanoma- BMS

    Bristol-Myers Squibb announced that the FDA approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab), for the treatment of patients with...

    Guidelines
    Guideline
    13/08/23

    Systemic therapy for melanoma: ASCO guideline update

    This ASCO guideline update reviews systemic therapy for melanoma, adding new recommendations for neoadjuvant pembrolizumab, adjuvant nivolumab or pembrolizumab, and combination regimens for advanced disease. It also removes outdated options like talimogene laherparepvec.

    • Source: American Society of Clinical Oncology (ASCO)
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    26/07/15

    EMA validates application from BMS for combination Opdivo (nivolumab) + Yervoy (ipilimumab) to treat advanced (unresectable or metastatic) melanoma .

    The EMA has validated the application from BMS for Opdivo (nivolumab) + Yervoy (ipilimumab) to treat melanoma, the proposed new...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    12/05/16

    EMA approves Opdivo + Yervoy (nivolumab + ipilimumab) for advanced melanoma- BMS

    Bristol-Myers Squibb announced that the European Commission (EC) has approved Opdivo + Yervoy (nivolumab + ipilimumab) for the treatment of...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    18/09/24

    Landmark 10-year follow-up data from CheckMate -067 which showed continued durable long-term survival benefit with Opdivo (nivolumab) + Yervoy (ipilimumab) in advanced melanoma

    Bristol Myers Squibb  announced 10-year follow-up data from CheckMate -067, a randomized, double-blind, Phase III clinical trial, which showed continued durable improvement in survival with first-line Opdivo  (nivolumab) plus Yervoy (ipilimumab) therapy and Opdivo monotherapy, versus Yervoy alone, in patients with previously untreated advanced or metastatic melanoma

    Journals
    Journal
    01/06/20

    Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

    This randomized phase II trial compares the efficacy of nivolumab alone versus nivolumab combined with ipilimumab in treating recurrent or persistent ovarian cancer. The study finds that the combination therapy significantly improves response rates and progression-free survival compared to nivolumab alone.

    • Source: Journal of Clinical Oncology
    See more